U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector transforms.
Related Posts
‘We really like the U.S.,’ Julius Baer portfolio manager says. Here’s where she sees opportunity
Julius Baer portfolio manager reveals the investment opportunities she sees now.
Asia-Pacific markets fall as Iran-Israel conflict dents investor sentiment
U.S. President Donald Trump is weighing a military strike on Iran, while demanding the country’s leader Ayatollah Ali Khamenei “surrender.”
Omada shares pop 42% in Nasdaq debut after health tech company’s IPO
Omada Health became the latest tech company to hit the Nasdaq on Friday, as the IPO market picks up steam.